Printer Friendly

Ortec Initiates Premarket Approval -PMA- Application Filing Seeking Approval for OrCel in Treating Venous Leg Ulcers.

Business Editors/Health/Medical Writers

BIOWIRE2K

NEW YORK--(BUSINESS WIRE)--Dec. 23, 2003

Approval Would Open U.S. Market Potential Estimated in Excess of $500

Million

Ortec International, Inc. (ORTN) announced today that it has initiated the filing of its Premarket Approval (PMA) application requesting permission from the Food and Drug Administration (FDA) to market its tissue engineered product, OrCel(R), for the treatment of venous leg ulcers, an estimated $500 million market in the U.S. Ortec submitted today the Manufacturing and Controls (CMC) section, the first of two modules of the application. The final section of the PMA, which will include a summary of safety and effectiveness in the clinical studies and device labeling, is expected to be filed with the FDA at the end of January 2004.

Ortec recently announced that in agreement with the FDA to expedite the review process, it is filing its PMA on a modular basis, wherein each section of the PMA is filed with the FDA as it is completed.

Ortec previously announced that in an analysis of the data from its Phase III clinical trial evaluating the cryopreserved version of OrCel in the treatment of chronic hard to heal venous leg ulcers, OrCel demonstrated a 64% improvement over standard of care and achieved statistically significant differentials for both the primary and secondary endpoints of the trial, time to 100% healing and the percentage of patients achieving 100% wound closure.

Ron Lipstein, Chief Executive Officer and Vice Chairman of Ortec International, commenting on the initiation of the filing of the PMA said, "The initiation of the PMA process is an achievement of a very significant milestone for Ortec towards gaining access to the venous leg ulcer market, a very sizeable population with unmet needs. Over the last few months, Ortec has accomplished a number of very critical value enhancing milestones including executing a commercial manufacturing agreement with Cambrex (NYSE: CBM), completion of our Phase III clinical trial for venous leg ulcers, and now filing our PMA for that indication. Looking forward to 2004, we expect to continue to successfully implement our business plan, gain approval from the FDA to market OrCel for venous leg ulcers, initiate commercial sales of OrCel for that market, and initiate a Phase III clinical trial for the use of OrCel in diabetic foot ulcers."

About Ortec International, Inc.

Ortec International, Inc., (ORTN), is a tissue-engineering company involved in the commercialization of a proprietary and patented technology to stimulate the repair and regeneration of human tissue. Ortec's current focus is the application of its OrCel(R) (Bilayered Cellular Matrix) to heal chronic and acute wounds. OrCel is composed of a collagen sponge seeded with allogeneic epidermal and dermal cells. These cells secrete growth factors and cytokines normally found in acute human wounds and are believed to have a beneficial role in promoting tissue repair. In addition to having received FDA approvals for the treatment of Epidermolysis Bullosa and donor sites in burn patients, a pivotal clinical trial has been completed for venous ulcers and the FDA has granted Ortec approval to initiate a pivotal trial in diabetic foot ulcers. Ortec believes that its platform technology may extend to the regeneration of other human tissue such as tendons, ligaments, cartilage, bone, muscle and blood vessels. For more information, visit Ortec's website at http://www.ortecinternational.com.

Certain statements made in this news release that express the belief, potential anticipation or expectation, as well as other statements which are not historical fact, and statements relating to the clinical trials and their results, design, FDA product approvals or other marketing approvals, features, functionality and performance insofar as they may apply prospectively, are "forward-looking" statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties. The Company's actual results may differ significantly from the results discussed in this news release or in other "forward-looking" statements presented by management. Factors that might cause such a difference include, but are not limited to, development by the Company's competitors of new technologies or products that are more effective than the Company's, risks of failure of clinical trials, dependence on and retention of key personnel, protection of proprietary technology, compliance with U.S. Food and Drug Administration regulations, continued availability of raw material for the Company's products, availability of product liability insurance in the event of commercialization of the Company's products, ability to effect transition from pilot-scale manufacturing to large-scale commercial production of products, uncertainty as to the availability of additional capital on acceptable terms, if at all, and the demand for the Company's products, if and when commercially available.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Dec 23, 2003
Words:777
Previous Article:ZiLOG Announces Proposed Public Offering of 8,000,000 Shares of Common Stock.
Next Article:Delta Dental Grants $125,000 to Community Dental Clinics; Funding Benefits the Working Poor in Pennsylvania, New York, West Virginia.
Topics:


Related Articles
ORTEC SUCCESSFULY DEFENDS EUROPEAN PATENT ON ORCEL.
Ortec Announces Completion of Patient Enrollment for its Phase III Venous Leg Ulcer Pivotal Trial; PMA Filing for OrCel on Track for 4Q 2003.
Clinical Results of Ortec's OrCel in Treating Foot Ulcers Featured in Peer Reviewed Journal 'Wounds'.
64% Improvement Over Standard of Care Therapy Achieved in Ortec's Venous Ulcer Pivotal Trial.
Ortec's Phase III Clinical Trial Data Presented at American Academy of Dermatology's Annual Meeting; Final Section of Ortec's PMA to be Filed This...
FDA Notifies Ortec of PMA Acceptance; Completion of First Step in PMA Approval Process Achieved.
Ortec Provides Update of PMA Status and Auditor Selection.
FDA Requests Confirmatory Trial for Approval of PMA for OrCel in the Treatment of Venous Ulcers.
Ortec Set to Initiate 60 Patient Confirmatory Trial For Venous Leg Ulcer Approval; Final Version of Study Protocol and Clinical Design Submitted to...
FDA Approves Ortec's Protocol and Initiation Of Confirmatory Trial of OrCel(R) for Venous Ulcers.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters